Expression of Cyclin D1, Cytokeratin 7, Cytokeratin 20 and Vimentin in Papillary Thyroid Cancer and Relationship with Patient's Prognostic Factors.
10.16956/kjes.2012.12.2.92
- Author:
Ho Jin KIM
1
;
Yoo Seok KIM
;
Se Won KIM
;
Kweon Cheon KIM
Author Information
1. Department of Surgery, Chosun University College of Medicine, Gwangju, Korea. kckim@chosun.ac.kr
- Publication Type:Original Article
- Keywords:
Papillary thyroid cancer;
Cyclin D1;
Cytokeratin 7;
Cytokeratin 20;
Vimentin
- MeSH:
Carcinogenesis;
Cyclin D1*;
Cyclins*;
Female;
Humans;
Keratin-20*;
Keratin-7*;
Keratins*;
Lymph Nodes;
Neoplasm Metastasis;
Prospective Studies;
Sample Size;
Thyroid Gland*;
Thyroid Neoplasms*;
Vimentin*
- From:Korean Journal of Endocrine Surgery
2012;12(2):92-96
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Cyclin D1, cytokeratin(CK)7, CK20 and vimentin play an important role in tumorigenesis and tumor progression. Our aim was to investigate the expression of cyclin D1, CK7, CK20 and vimentin in 138 papillary thyroid cancer and relationship with clinicobiological factors. We also tried to evaluate the value of those as prognostic factors. METHODS: We performed an immunohistochemical assay for cyclin D1, CK7, CK20, and vimentin in 138 papillary thyroid cancer tissue specimens. The correlation between these factors and the clinicobiological parameters was analyzed. RESULTS: In 138 papillary thyroid carcinoma specimens, the expression of cyclin D1, CK7, CK20 and vimentin was seen in 118 cases (85.5%), 133 cases (96.4%), 2 cases (1.4%) and 119 cases (86.2%), respectively. In our cases, there was a significant association among the expressions of cyclin D1, gender and lymph node metastasis. However, no obvious correlation was found between those proteins, age, tumor size, tumor amount, lymph node status and the TNM stage. CONCLUSION: Our results suggested increased cyclin D1 expression was seen in female gender and it may be a useful marker for evaluating lymph node metastasis. However, the clinical utility of cyclin D1, CK7, CK20 and vimentin in thyroid cancer patients has to be further defined by prospective studies with larger sample sizes.
